



# LUND UNIVERSITY

AFFIRM – a multiplexed immunoaffinity platform that combines recombinant antibody fragments and LC-SRM analysis

Säll, Anna; Carlsson, Fredrika; Olsson, Niclas; Wingren, Christer; Ohlin, Mats; Persson, Helena; Waldemarson, Sofia

*Published in:*  
Journal of Proteome Research

*DOI:*  
[10.1021/pr500757s](https://doi.org/10.1021/pr500757s)

2014

[Link to publication](#)

*Citation for published version (APA):*

Säll, A., Carlsson, F., Olsson, N., Wingren, C., Ohlin, M., Persson, H., & Waldemarson, S. (2014). AFFIRM – a multiplexed immunoaffinity platform that combines recombinant antibody fragments and LC-SRM analysis. *Journal of Proteome Research*, 13(12), 5837-5847. <https://doi.org/10.1021/pr500757s>

*Total number of authors:*  
7

## General rights

Unless other specific re-use rights are stated the following general rights apply:  
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

## Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

**AFFIRM – a multiplexed immunoaffinity platform that combines recombinant antibody fragments and LC-SRM analysis**

Journal:	<i>Journal of Proteome Research</i>
Manuscript ID:	pr-2014-00757s.R1
Manuscript Type:	Article
Date Submitted by the Author:	21-Oct-2014
Complete List of Authors:	Säll, Anna; Immunotechnology, Carlsson, Fredrika; The Scripps Research Institute, Department of Cell Biology; Immunotechnology, Olsson, Niclas; Stanford School of Medicine, Department of Chemical and Systems Biology; Immunotechnology, Wingren, Christer; Lecturer (Univ. Lektor), Dept. of Immunotechnology Ohlin, Mats; Lund University, Dept of Immunotechnology Persson, Helena; Lund University, Dept of Immunotechnology Waldemarson, Sofia; Immunotechnology, Immunotechnology

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

# AFFIRM – a multiplexed immunoaffinity platform that combines recombinant antibody fragments and LC-SRM analysis

33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

*Anna Säll<sup>‡</sup>, Fredrika Carlsson<sup>‡1</sup>, Niclas Olsson<sup>2</sup>, Christer Wingren, Mats Ohlin,*

*Helena Persson<sup>†</sup>, Sofia Waldemarson<sup>†\*</sup>*

Department of Immunotechnology, Lund University, Medicon Village (House 406), 223 81  
Lund, Sweden

*E-mail addresses:*      Anna.Sall@immun.lth.se (Anna Säll)  
fredrika@scripps.edu (Fredrika Carlsson)  
nolsson@stanford.edu (Niclas Olsson)  
Christer.Wingren@immun.lth.se (Christer Wingren)  
Mats.Ohlin@immun.lth.se (Mats Ohlin)  
Helena.Persson@immun.lth.se (Helena Persson)  
Sofia.Waldemarson@immun.lth.se (Sofia Waldemarson)

52  
53  
54  
55

## KEYWORDS

56  
57  
58  
59  
60

Affinity proteomics, SRM, scFv, serum, biomarker

1  
2  
3 ABSTRACT  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Targeted measurements of low abundance proteins in complex mixtures are in high demand in many areas, not the least in clinical applications measuring biomarkers. We here present the novel platform AFFIRM (AFFInity sRM) that utilizes the power of antibody fragments (scFv) to efficiently enrich for target proteins from a complex background and the exquisite specificity of SRM-MS based detection. To demonstrate the ability of AFFIRM, three target proteins of interest were measured in a serum background in single- and multiplexed experiments in a concentration range of 5-1000 ng/ml. Linear responses were demonstrated down to low ng/ml concentrations with high reproducibility. The platform allows for high throughput measurements in 96-well format and all steps are amendable to automation and scale-up. We believe the use of recombinant antibody technology in combination with SRM MS analysis provides a powerful way to reach sensitivity, specificity and reproducibility as well as the opportunity to build resources for fast on-demand implementation of novel assays.

## INTRODUCTION

Quantitative measurements of specific target proteins with high precision and quantitative accuracy have a wide range of application areas, not the least in clinical research and analysis. Proteins carrying clinical information, referred to as biomarkers, hold the promise to revolutionize medicine if clinically implemented. Developing assays for measuring these however still remains challenging <sup>1</sup>. Biomarkers need to be assessed in large sample cohorts with high accuracy and reproducibility, and combining several biomarkers can potentially increase the precision. For true clinical utility, these proteins should also preferably be measurable in an easily accessible body fluid such as blood for a minimally invasive test. This poses further challenges as serum or plasma samples represent proteins in a dynamic range of over 10 orders of magnitude <sup>2</sup>. Hypothesizing that the target proteins are produced at the site of disease and shed into the blood stream, the enormous dilution effect makes them likely to be present in the low ng/ml concentration or below <sup>2,3</sup>. These requirements all place enormous demands on technology to deliver accurate and reproducible data yet with relatively high throughput.

Immunoassays, often sandwich enzyme-linked immunosorbent assays (ELISA), are today considered golden standard for quantitative clinical measurements of proteins in solution <sup>4,5</sup>. Despite their extensive utility, these assays suffer from certain shortcomings. High-quality ELISAs normally require pairs of antibodies <sup>6</sup>. However, development of appropriate antibody pairs having high enough sensitivity and specificity is a demanding task. Multiplexing ELISAs also remains challenging <sup>7</sup>. In addition, many disease-related proteins are post-translationally modified, truncated or are present in active or inactive forms depending on sequence variations. These variants might be the ultimate discriminatory biomarkers <sup>8-10</sup>. However, most antibodies are unable to discriminate between such small sequence deviations.

1  
2  
3 Mass spectrometry (MS) based technologies have therefore been proposed as an attractive  
4 alternative to ELISA. In particular, for more quantitatively accurate measurements selected  
5 reaction monitoring (SRM) mass spectrometry, also known as multiple reaction monitoring  
6 (MRM), has increasingly been applied to measure predetermined sets of proteins. SRM has  
7 high multiplexing capability and can measure up to hundreds of proteins in one single  
8 analysis, is highly specific through its sequence based readout and has been demonstrated to  
9 provide reproducible measurements<sup>11,12</sup>. This technology has routinely been used in the clinic  
10 for years for high-throughput quantification of metabolites in plasma<sup>13</sup>. SRM has more  
11 recently been demonstrated to also provide measurements of peptides in plasma with the  
12 precision and reproducibility and the transferability between laboratories required for clinical  
13 utility<sup>12,14-16</sup> and can provide highly sensitive measurements in the low ng/ml range<sup>17,18</sup>. This,  
14 however, requires extensive sample workup and peptide separation, procedures that are hardly  
15 amenable to high-throughput analysis. Therefore targeted enrichment has often been  
16 combined with SRM readout<sup>19</sup>.

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34 Antibodies possess the unique property of selectively binding proteins with high specificity  
35 and sensitivity, and they can thus be used to increase the selectivity and sensitivity of an  
36 assay. The attractive prospect of combining the sensitivity of antibody enrichment with the  
37 specificity of mass spectrometry has fueled the development of platforms for targeted  
38 analyses with the aim of providing robustness and throughput for quantitative protein  
39 measurements<sup>19-23</sup>.

40  
41  
42  
43  
44  
45  
46  
47 Here we present a novel developed platform, AFFIRM (AFFInity sRM), that combines  
48 protein enrichment by specific recombinant antibody fragments, in form of single chain  
49 variable fragments (scFvs), generated in house by phage display technology<sup>24,25</sup>, with liquid  
50 chromatography (LC)-SRM MS readout. An scFv is a fusion protein of the variable domains  
51 of the heavy and light chains of an antibody that are connected by a short peptide linker.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Despite the removal of the constant domains, this protein retains the specificity of the original  
4 antibody. Such recombinant antibody fragments represent a sustainable resource that allows  
5 fast production and is amenable to high-throughput generation of specific binders<sup>26-29</sup>. The  
6  
7 AFFIRM platform has been developed for a high-throughput workflow in a 96-well format  
8 using a magnetic bead processor for complete automation of capture and wash steps (Figure  
9  
10 1). In this proof-of-concept study, six recombinant scFvs were developed against three target  
11 proteins. Each scFv was coupled to magnetic beads and used to capture the corresponding  
12 target protein from a serum background in both a single- and multiplexed fashion. The  
13 captured proteins were digested directly on the beads followed by direct LC-SRM peptide  
14 analysis for protein quantification, providing a completely automated protocol performed  
15 within one day. By making use of recombinant antibody fragments for enrichment of target  
16 proteins in combination with quantification through SRM, this integrated platform promises  
17 to be an attractive alternative for quantitative measurements of clinical biomarkers in complex  
18 backgrounds such as plasma or serum.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## EXPERIMENTAL PROCEDURES

*Proteins* - Three target proteins, human keratin-19 (KRT19) (ProSpec-Tany TechnoGene Ltd., Rehovot, Israel), the C-terminal located BRCT domain of human breast cancer type 1 susceptibility protein (BRCA1) (kindly provided by Michael Sandrini, University of Copenhagen, Denmark) and the extra-cellular domain of 32 tandem repeats of human mucin-1 (MUC1) fused to a mouse IgG<sub>2a</sub> Fc region (MUC-Fc)<sup>30</sup>, kindly provided by Gunnar C. Hansson (Gothenburg University, Sweden) were used in this study.

*Synthetic antibody libraries* – Two different human synthetic scFv libraries were used for phage selections on the three target proteins. For selections on KRT19 the in-house designed and constructed HELL-11 library (Säll and Persson *et al*, manuscript in preparation), was used. In short, built on the framework of immunoglobulin genes IGHV3-23 and IGK1-39, diversity was added into defined codons in four of the six complementarity determining regions (CDR); CDR-H1, CDR-H2, CDR-H3 and CDR-L3, using a tailored oligonucleotide mixture together with an optimized Kunkel mutagenesis methodology as previously explained<sup>58, 59</sup>. The procedure yielded a highly diverse repertoire containing  $>1 \times 10^{10}$  unique members, as measured by the number of bacterial colonies obtained after transformation. For selections on BRCA1 and MUC1-Fc an antibody library synthesized by GENEART AG (Regensburg, Germany) was used. Based on a crystal structure of a MUC1 specific scFv (Wingren *et al.*, unpublished), a total fourteen surface-exposed residues, were diversified in the three CDRs of the heavy chain (IGHV3-23), and the third CDR of the light chain (IGLV1-47), giving a theoretical diversity of  $1 \times 10^{11}$ . In practice, a library size of  $1 \times 10^{10}$  was obtained. The bacteria harboring the libraries were infected with M13K07 helper phages (New England Biolabs,



1  
2  
3 Ipswich, MA, USA) and scFv displaying phages were harvested by standard polyethylene  
4 glycol/NaCl precipitation.  
5  
6  
7  
8

9  
10 *Selection of specific binders using phage display* – Phage display selections were performed  
11 on KRT19, BRCA1 and MUC1-Fc using two different selection procedures. In short, the  
12 antigens (KRT19 and BRCA1) were either immobilized in immunotubes (Nunc A/S,  
13 Roskilde, Denmark) or coupled (MUC1-Fc) to magnetic Pan Mouse IgG beads Dynabeads  
14 (Dynal A/S, Oslo, Norway). Prior to the selection, the phage stocks were incubated with  
15 streptavidin immobilized in immunotubes or against Pan Mouse IgG beads but with no  
16 antigen for 1 hour at room temperature and slow rotation. Subsequently, the phage stock was  
17 transferred to the antigen-coated immunotubes or to the antigen coated magnetic beads and  
18 incubated for 2 h at room temperature and slow rotation. The immunotubes and magnetic  
19 beads were washed 6-11 times. Bound phages were eluted by trypsin, which cleaves the  
20 trypsin-sensitive site located between the displayed scFv and gene III, amplified in solution  
21 over night at 30 °C, PEG-precipitated, resuspended in PBS containing 0.1-0.5% BSA (w/v)  
22 and used for subsequent rounds of selection as described above. In total, four rounds of  
23 selection were carried out for KRT19, three rounds of selection for BRCA1 and two rounds of  
24 selection for MUC1-Fc. For each selection round the amount of antigen was gradually  
25 decreased and the number of washes increased.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 *Production and purification of soluble antibody fragments* – Vectors encoding scFv specific  
48 for KRT19 and BRCA1 were digested with *Sfi*I and *Avr*II and subsequently re-ligated into a  
49 vector that allows for production and purification of soluble scFv. In order to remove gene 3  
50 from the phagemids encoding the MUC1-Fc specific scFv, these were digested with *Eag*I and  
51 re-ligated. Both these procedures provide the secreted scFv with a hexahistidine tag at the C-  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 terminus, preceded by either a trippel-FLAG tag or a single FLAG tag. The constructs were  
4  
5 transformed into Top10 *E.coli* and soluble scFv were produced and purified essentially as  
6  
7 described<sup>31</sup>. The integrity and purity of the scFv was confirmed by SDS-PAGE.  
8  
9

10  
11 *Immunoassay to determine specific binding of selected scFv* – In order to evaluate the  
12  
13 specificity of the generated scFv, individual phage-displayed scFv clones or their soluble  
14  
15 counterparts were screened for binding specificity in ELISA. 96- or 384-well plates (Corning  
16  
17 Inc., New York, NY, USA) were immobilized with recombinant KRT19, BRCA1, MUC1 or  
18  
19 with BSA and incubated overnight. Unbound proteins were removed by washing and the  
20  
21 wells were blocked with BSA. Phages displaying scFv or soluble scFv were allowed to bind  
22  
23 and after another round of washing HRP-labeled mouse anti-M13 monoclonal antibody (GE  
24  
25 Healthcare, Buckinghamshire, UK), HRP-labeled mouse anti-FLAG antibody (Sigma-  
26  
27 Aldrich, St. Louis, MO, USA) or HRP-labeled mouse anti-His<sub>6</sub> antibody (Roche Applied  
28  
29 Science, Sweden) were applied to determine the level of bound phages or scFv. Ultra TMB-  
30  
31 ELISA (Thermo Scientific Pierce, Rockford, IL, USA) was used as chromogen. The reaction  
32  
33 was stopped by the addition of 2 M sulfuric acid and the absorbance was measured at 450 nm.  
34  
35  
36  
37  
38  
39

40  
41 *Selection of target peptides and transitions* – Peptides and transitions relevant for analysis  
42  
43 of KRT19, BRCA1 and MUC1-Fc were selected in the SRM management software Skyline  
44  
45<sup>32</sup>. An *in-silico* trypsin digestion of the target proteins allowing peptides of 7-25 amino acids  
46  
47 length was performed and peptides with C, M, H, NXT/NXS or RP/KP in the sequence were  
48  
49 removed. The peptides were checked against a background proteome of the entire human  
50  
51 proteome (UniProt KB download) to ensure that truly unique proteotypic peptides were  
52  
53 selected for each protein. MS/MS data of digested recombinant target proteins was obtained  
54  
55 on a Thermo LTQ Orbitrap XL mass spectrometer (Thermo Electron, Bremen, Germany)  
56  
57  
58  
59  
60

1  
2  
3 coupled to an Eksigent 2D NanoLC system (Eksigent technologies, Dublin, CA, USA),  
4  
5 equipped and run as described below for LC-SRM. This data was used to select peptide  
6  
7 charge-state and their 4-5 best transitions. The final number of target peptides was narrowed  
8  
9 down to three peptides for KRT19 and two for BRCA1 plus two mouse IgG peptides that  
10  
11 were used for measuring the MUC1-Fc fusion protein (Table 1). In addition to the peptides  
12  
13 representing the target proteins, peptides for three proteins (apolipoprotein B-100,  
14  
15 Immunoglobulin gamma-1 chain C region and Complement C3) were identified. These  
16  
17 proteins are highly abundant in serum and they were identified in the captured material likely  
18  
19 due to non-specific binding. These targets were included in the SRM assay represented by one  
20  
21 peptide each. Two peptides representing clones specific for either KRT19 or BRCA1/MUC-  
22  
23 Fc were also included, giving a final SRM assay consisting of 12 peptides and 81 transitions.  
24  
25 Collision energies were optimized through Skyline using trypsin digests of the recombinant  
26  
27 proteins. Protein names, peptide sequences, transitions and collision energies are given in  
28  
29 Supplementary Table S1.  
30  
31  
32  
33  
34  
35

36 *Capture of target proteins in a serum background* – Purified soluble scFv were coupled to  
37  
38 magnetic Dynabeads M-270 Epoxy beads (Invitrogen Dynal AS, Oslo, Norway) according to  
39  
40 manufacturer's protocol. Briefly, coupling was performed by mixing 0.9 mg beads with 0.1 M  
41  
42 sodium phosphatase (pH 7.4), 20 µg scFv and 1 M ammonium sulfate. The mixture was  
43  
44 incubated over night. The two scFvs developed against the same target protein were mixed  
45  
46 before coupling. Capture of spiked proteins in serum was carried out using a KingFisher  
47  
48 magnetic bead processor (Thermo Scientific, Waltham, MA, USA). The automated steps  
49  
50 included two washes of the 20 µl scFv-coupled beads used for each capture, in 1 PBS  
51  
52 containing ml 0.05% (v/v) Tween20. Following the washes, the beads were incubated in 10%  
53  
54 (v/v) human serum (Sigma-Aldrich Corp, St. Louis, MO USA) diluted in PBS and spiked  
55  
56  
57  
58  
59  
60

1  
2  
3 with target proteins at a concentration of 0, 5, 25, 50, 100, 500, 1000 ng/ml for 1 h. The beads  
4  
5 were washed 4 times in PBS containing 0.03% CHAPS (w/v) and once in 50 mM ammonium  
6  
7 bicarbonate containing 0.03% (w/v) CHAPS and subsequently transferred to Axygen  
8  
9 maximum recovery tubes. The wash solution was removed prior to addition of 15  $\mu$ l 12 ng/ml  
10  
11 trypsin (sequencing grade modified, Promega Corp, Madison, WI, USA). Trypsin digestion  
12  
13 was performed at 37°C for 4 h at which time another 5  $\mu$ l trypsin was added and the digestion  
14  
15 was continued for an additional 1 h. 2  $\mu$ l 5% (v/v) formic acid (FA) was added, the samples  
16  
17 were dried and reconstituted in 15  $\mu$ l 0.1% (v/v) FA, 3% (v/v) acetonitrile (ACN) and  
18  
19 transferred to HPLC vials for LC-SRM. For multiplexed captures 20  $\mu$ l scFv-coupled beads  
20  
21 per target protein were mixed and used for capture. 30  $\mu$ l 12 ng/ml trypsin was used followed  
22  
23 by another 5  $\mu$ l addition after 4 h, the samples were dried and reconstituted in 15  $\mu$ l 0.1% FA,  
24  
25 3% ACN. 6  $\mu$ l sample was injected for LC-SRM analysis.  
26  
27  
28  
29  
30  
31  
32

33 *Serum dilution curves* – 10% serum was spiked with the three target proteins at a  
34  
35 concentration range of 5-100 000 ng/ml (5, 25, 50, 100, 500, 780, 1560, 3125, 6250, 12500,  
36  
37 50000, 100000 ng/ml). Captures were also performed from serum with no spiked proteins to  
38  
39 provide blank measurements. The samples were digested. Briefly, dried samples were  
40  
41 reconstituted in 6M urea, 100 mM Tris, pH 8 and incubated at 37°C for 30 min. The samples  
42  
43 were diluted 10x in 100 mM Tris, pH 8 and trypsin was added at a trypsin/sample ratio of  
44  
45 1:50. The sample were digested over night (16h) and 10% (v/v) FA was added to a pH of 3.  
46  
47 The samples were cleaned using C18 UltraMicroSpin Columns, 3-30  $\mu$ g capacity (The Nest  
48  
49 Group). The peptides were dried and reconstituted in 0.1% FA, 3% ACN and transferred to  
50  
51 HPLC vials for LC-SRM using the same setup as for the AFFIRM assay. An equivalent of 1  
52  
53  $\mu$ g total protein was injected.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3        *Nano-LC-SRM* – An Eksigent 2D NanoLC system (Eksigent technologies, Dublin, CA,  
4 USA) connected to a Triple Stage Quadrupole Mass Spectrometer (TSQ Vantage, San José,  
5 CA) was used for LC-SRM analysis. Solvents used were water/0.1% FA (v/v) (mobile phase  
6 A) and ACN/0.1% (v/v) FA (mobile phase B). The LC system was equipped with a trapping  
7 column (0.3 mm id, 5 mm, PepMap Acclaim C18, LCPackings, Sunnyvale, CA). Analytical  
8 columns were packed in-housed in 0.075 mm id, 100 mm PicoFrits (New Objective, Woburn,  
9 MA) with 3 µm ReproSil C18-AQ particles (Dr. Maisch, Germany) to a length of 12 cm. The  
10 LC gradient was delivered at 300 nl/min and consisted of a linear gradient of mobile phase B  
11 developed from 3–35% B during 22 min and from 45-90% during 8 min. An injection for  
12 wash and equilibration of the column was performed between each sample. The Triple Stage  
13 Quadrupole Mass Spectrometer (TSQ Vantage, San José, CA) was equipped with a nano  
14 electrospray interface operated in the positive ion mode with a spray voltage of 1.8 kV and an  
15 ion capillary temperature of 270 °C. Both Q1 and Q3 were set to unit resolution (0.7 Da) and  
16 10 ms dwell time was used. Data were acquired using the Xcalibur software (version 2.0.7).  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36        *Data Analysis* – Raw files from SRM data acquired on the TSQ Vantage were analyzed and  
37 manually inspected in Skyline. Peak areas for the measured SRM transitions for each  
38 individual peptide were integrated and summed to generate the peptide peak areas. Data was  
39 exported from Skyline as .csv files and response curves for the different proteins' spike levels  
40 were plotted to monitor the linearity of the response.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

We present here the immunoaffinity SRM platform AFFIRM developed for quantification of low-abundance proteins of interest in complex samples such as serum. This is done in an assay format where target proteins are enriched using human recombinant scFv coupled to magnetic beads with subsequent on-bead trypsin digestion and LC-SRM readout. As part of the AFFIRM platform, we continuously develop in-house scFv and SRM assays against target proteins of interest (Figure 1A). Once developed, these resources are used for building an assay that can quickly be established in a plug-and-play fashion with minimum preparative steps (Figure 1B). The AFFIRM assay is automated and optimized for minimum sample handling and high-throughput (Figure 1C). Three target proteins, KRT19, BRCA1 and MUC1-Fc (Table 1), were used to demonstrate the proof-of-concept of this novel platform.

*Selection and screening of protein specific scFv* – Human recombinant antibody fragments against KRT19, BRCA1 and MUC1-Fc were generated from in-house designed antibody libraries using phage display technology. Based on performance in an initial phage ELISA analysis, two scFvs specific for each antigen were chosen for sub-cloning and evaluation for the intended application. ELISA of the soluble expressed scFv verified specific recognition of the three targets (Figure 2). ScFv specific for the MUC1-Fc fusion protein were shown in separate experiments to recognize synthetic peptides covering the MUC-1 repeat sequence in the absence of the Fc (data not shown). Sequence analysis of the specific clones further verified uniqueness of the six clones (data not shown).

*SRM analysis* – Each target protein was measured through 2-3 proteotypic peptides with 4-5 transitions each (Table 1). In addition, one peptide from each of the three serum proteins, Apolipoprotein B-100, Immunoglobulin G1 and Complement C3 that gave the highest

1  
2  
3 background signals in the orbitrap experiments were included (data not shown), as well as  
4  
5 two peptide representing the scFvs.  
6  
7

8  
9  
10 *The AFFIRM assay workflow* – Enrichment of recombinant proteins from human serum  
11 samples were performed in an automatic KingFisher bead processor. The 90-minute  
12 processing included automatic washing of antibody fragments coupled to magnetic beads, a 1-  
13 h binding cycle, followed by five wash steps to minimize background signal. The beads were  
14 transferred to the Axygen tubes and the captured proteins were digested directly on the beads  
15 with trypsin for 5 h. This digestion protocol was the final choice of several tested, including  
16 elution of target protein followed by digestion with or without reduction and alkylation (data  
17 not shown). In addition to being the fastest protocol, the elution step before trypsin digestion  
18 can be omitted and, thus, variations due to incomplete elution, pipetting and protein adhesion  
19 to the tubes are avoided<sup>33</sup>. Five hours of trypsin digestion also gave superior results compared  
20 to over night digestion, probably due to the low sample complexity after protein enrichment  
21 and the multiple wash steps. After digestion the magnetic beads were removed and the digest  
22 was acidified, dried and reconstituted for LC-SRM readout of the target peptides. The  
23 chromatographic gradient was 30 min in these experiments, but a shorter gradient of 12 min  
24 was also successfully applied for improved sample throughput purposes (data not shown).  
25 Resulting data was analyzed in the Skyline software<sup>32</sup>. The chromatograms demonstrated  
26 very high reproducibility with 1.1-2.0 %CV in the chromatographic retention times, as well as  
27 in the general pattern of the signals of the different transitions and the correct peptide peaks  
28 could easily be identified as shown in Figure 3.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52  
53  
54 *Response curves* – Response curves were generated to monitor the linearity of the signal  
55 response over a concentration range of 5-1000 ng/ml (Figure 4-5). The two scFvs developed  
56  
57  
58  
59  
60

1  
2  
3 against each target protein were mixed before coupling to magnetic beads and used for  
4  
5 capture of the three target proteins (KRT19, MUC1-Fc and BRCA1) individually (Figure 4).  
6  
7 All peptides for all target proteins were easily detected down to the lowest concentration (5  
8  
9 ng/ml) with good linearity over the selected range. For the multiplexed captures, the magnetic  
10  
11 beads coupled with the scFv of different specificity were mixed and used to capture the three  
12  
13 target proteins over the same concentration range (Figure 5). Two out of the three peptides  
14  
15 used to monitor KRT19 were detected down to the lowest concentration and all three peptides  
16  
17 showed excellent linearity. The two peptides used to monitor MUC1-Fc were also detected  
18  
19 over the entire range with good linearity while the two BRCA1 peptides, although detectable  
20  
21 over the entire range demonstrated a somewhat poorer linearity. The curves were made in  
22  
23 triplicate from the very beginning of the protocol generating overall AFFIRM assay median  
24  
25 CVs between 7-18.2%, excluding one BRCA1 peptide with an outlying CV as summarized in  
26  
27 Table 1. The blank captures, i.e. captures with no spiked-in target proteins, gave a very low  
28  
29 degree of background signal indicating clean captures with a low degree of interferences. This  
30  
31 was also true for multicaptures as shown in Figure 3. Also, the peptides representing the scFv  
32  
33 and the three serum proteins that dominated the background signal gave very stable signals in  
34  
35 all captures (data not shown).  
36  
37  
38  
39  
40  
41  
42

43 *Relative protein enrichment* - To estimate the relative enrichment achieved by the antibody  
44  
45 in the captures, the three target proteins were analyzed in a serum background with no prior  
46  
47 captures. A dilution series ranging from 5 ng/ml to 100 000 ng/ml was constructed to  
48  
49 determine the limit of detection (LOD) of the target proteins in serum. The samples were  
50  
51 digested, cleaned and analyzed using LC-SRM. KRT19 was barely detected at all in these  
52  
53 samples, only one peptide could be detected at a spiked-in concentration of 100 000 ng/ml. As  
54  
55 illustrated in Figure 4, all three of the target proteins could with AFFIRM easily be detected  
56  
57  
58  
59  
60



1  
2  
3 down to 5 ng/ml, the lowest concentration tested. Thus, the limit of detection of the AFFIRM  
4  
5 capture samples is 5 ng/ml at least, equaling an enrichment factor of at least 20 000 for  
6  
7 KRT19. For BRCA1 both peptides were detected at a spiked-in concentration of 500 ng/ml,  
8  
9 which equals an enrichment factor of at least 100. For MUC1-Fc the results were difficult to  
10  
11 interpret for one of the peptides and the limit of detection in serum was 780ng/ml, whereas for  
12  
13 the other peptide the detection limit was 12 500 ng/ml. This corresponds to an enrichment  
14  
15 factor ranging between 156-2500.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

Sensitive and specific measurements of proteins of interest are greatly needed in many application areas. In the search and establishment of novel biomarkers for the clinic, lack of technology remains a major bottleneck and an intermediate verification step to move potential protein biomarkers from discovery studies towards true clinical qualification has been suggested<sup>34</sup>. This calls for technologies that meet several requirements such as sensitivity, specificity, multiplexing ability and throughput. In this work, we present the development of the novel immunoaffinity platform AFFIRM, combining targeted protein enrichment using scFvs with SRM readout for specific and sensitive protein analysis in both a single- and multiplexed format. The AFFIRM assay has been optimized to make the workflow fast and automated for increased throughput, reproducibility and cost efficiency.

AFFIRM takes advantage of the two powerful technologies recombinant antibody technology and MS. Both of these technologies are well established in the field of proteomics and the combination of the two has shown great capacity as a non-targeted fractionation strategy analyzing previously unexplored parts of the proteome<sup>35,36</sup>. This is, however, to the best of our knowledge, the first time that recombinant antibody technology has been combined with targeted MS readout through SRM analysis to create a platform for targeted protein enrichment and quantification in a multiplexed and flexible assay format.

SRM MS analyses have been demonstrated to reliably produce accurate measurements of target proteins of interest from complex biological samples such as tissue, cells or serum<sup>12,18,37-40</sup>. In addition, SRM can produce isoform specific readout<sup>8</sup> or information on post-translational modifications<sup>41</sup>. This is of central importance in any biological study trying to understand molecular interactions and signaling networks. In the search for novel biomarkers this discriminatory power provides unparalleled opportunities through the specific monitoring

1  
2  
3 of proteins that are unique to the disease state and maybe even the drivers of the disease itself  
4  
5 as in the case of cancer specific mutations <sup>8,9,23</sup>.  
6

7 For any platform using immunoaffinity enrichment, antibody availability continues to be a  
8 bottleneck. However, with the advent of *in vitro* display technologies <sup>42</sup> it is now possible to  
9 rapidly generate monoclonal recombinant antibody fragments against virtually any antigen. In  
10 comparison to immunization-based methods, namely polyclonal antibodies and monoclonal  
11 antibodies (mAbs), which in the past have been the major source of specific binders for the  
12 use as capture reagents <sup>43-45</sup>, recombinant methods for binder generation have a number of  
13 advantages. For example, polyclonal antibody preparations contain a diverse population of  
14 target-specific and non-target specific antibodies and may suffer from batch-to-batch  
15 variations <sup>46,47</sup>, thus requiring re-validation upon each production round. This is, in contrast to  
16 recombinant antibody fragments and mAb, which provide a continuous and renewable source  
17 of antibodies. Further, *in vitro* display techniques allow control over the selection process to a  
18 higher extent and the ability to enforce antibody fragments with desired properties by fine-  
19 tuning the selection approach. In addition, *in vitro* selection methods provide direct access to  
20 the antibody gene sequence, which is required for subsequent genetic modifications that  
21 might be needed to improve binder characteristics or assay compatibility.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 Importantly, *in vitro* display systems enables for high-throughput generation of specific  
41 binders, towards a large number of biological markers at the same time, by the use of  
42 automated systems <sup>26-29</sup>. This capability has opened up for creating large collections of  
43 specific probes against virtually the entire proteome. Examples of such large-scale efforts are  
44 the EU funded initiative AFFINOMICS <sup>48</sup> and the NIH Commons Fund's Protein Capture  
45 Reagents Program in the USA <sup>49</sup>. The ultimate goal of these initiatives is to create large  
46 standardized collections of well-validated binding molecules to be available for the research  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 society. Once these target specific probes have been developed, they can easily be produced  
4  
5 within a few days and used as a plug-and-play tool for immunoassays such as AFFIRM.  
6

7  
8 Targeted MS based immune-capture assays are designed to enrich either on protein- or  
9  
10 peptide-level. In this work, the AFFIRM platform has been presented using protein  
11  
12 enrichment, although, in principle, the workflow can also be applied on peptides. In our view,  
13  
14 enrichment on protein level offers several advantages. The development of high quality  
15  
16 binders for targeting peptides is generally more challenging than the development of protein  
17  
18 antibodies. This can be explained by a lack of extensive three-dimensional structure of many  
19  
20 peptides. From a target point of view, protein enrichment allows for detection of protein  
21  
22 variants that could, as already mentioned, be the ultimate biomarkers. Without prior  
23  
24 knowledge of these isoforms or modification this information can easily be over-looked using  
25  
26 peptide enrichment. Protein enrichment also makes the assay more flexible, reliable and  
27  
28 robust through multiple peptide readout for each target protein allowing the use of the best  
29  
30 performing peptides in any assay setup. The BRCA1 protein enrichment in this work  
31  
32 exemplifies this. Both BRCA1 peptides perform equally well in the single BRCA1 capture  
33  
34 (Figure 4C), while one of the peptides clearly does not give satisfactory results in the  
35  
36 multiplexed assay and should therefore be omitted for protein quantification in this setting  
37  
38 (Figure 5C). Also capturing proteins rather than peptides has the advantage that only the  
39  
40 captured fraction of the sample needs to be digested, thus allowing for scaling up the sample  
41  
42 volume to achieve higher sensitivity<sup>23</sup>. Less amounts of expensive enzyme are required and  
43  
44 the reduced complexity of the samples allows for much faster digestion (5 h compared to the  
45  
46 12-18h usually applied in complex mixtures). In addition, in this work the digestion after  
47  
48 protein capture was performed with no reduction and alkylation, as this require no sample  
49  
50 cleanup which saves both time and sample-processing steps that may introduce variability  
51  
52 into the assay. This being said, peptide captures have been successfully implemented in many  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 studies<sup>20,21</sup> and is in some case the preferred choice, for example when targeting highly  
4  
5 unstable proteins or proteins prone to denaturation<sup>22</sup>.  
6

7  
8 Mass spectrometry-based quantification often includes the use of heavy isotope labeled  
9  
10 target peptides<sup>12,19,23,50,51</sup>. These are useful as internal standards both to aid in identifying the  
11  
12 correct chromatographic peaks of the target peptides and for quantification using the ratio  
13  
14 between the light analytical signal and the heavy signal of known concentration for each  
15  
16 peptide. This is especially useful in the case of peptide centric capture experiments as the  
17  
18 heavy isotope peptides can be introduced already before capture and therefore account for  
19  
20 losses during enrichment. The digestion efficiency is however not controlled for. Heavy  
21  
22 peptides can also aid in protein captures both for peak identification and as a means to  
23  
24 normalize for when calculating run to run variation<sup>23</sup> and will be incorporated into the  
25  
26 AFFIRM platform in the future for further quality control. The ideal internal reference for  
27  
28 absolute quantification would be to spike samples with heavy isotope labeled target proteins  
29  
30 to also account for losses in the digestion process<sup>51,52</sup>. Such labeled proteins are however  
31  
32 very expensive.  
33  
34  
35

36  
37 The AFFIRM experiments provided detection of all three target proteins down to 5 ng/ml,  
38  
39 which was the lowest concentration explored. The relative enrichment was however very  
40  
41 spread with enrichment factors ranging between 100-20000 as the target proteins were  
42  
43 differently well detected directly in spiked serum. This is probably due to a combination of  
44  
45 factors, such as the digestion efficiency of the individual proteins in the complex sample  
46  
47 mixture<sup>52</sup> and the affinity of the scFvs for their respective targets. The difference in detection  
48  
49 of different peptides from the same protein, as seen with the two MUC-Fc peptides, also  
50  
51 highlights how different peptides are differently accessible to MS analysis. For selected  
52  
53 proteins, quantification down to hundreds of ng/ml has been reported by LC-SRM analysis  
54  
55 alone<sup>53</sup>. Additional upfront depletion<sup>54</sup> and/or fractionation<sup>54,55</sup> can further improve  
56  
57  
58  
59  
60

1  
2  
3 detection limits to reach the high pg/ml to the low ng/ml range. Immunoaffinity enrichment  
4  
5 has been demonstrated to provide sensitivities in the low ng/ml range <sup>40,56</sup>. Importantly,  
6  
7 targeted immunoaffinity protocols provide a more selective enrichment and can make way for  
8  
9 MS analysis of inherently difficult proteins. In addition, immunoaffinity enrichment  
10  
11 efficiently reduces sample complexity to make it more easily adapted to fast and automated  
12  
13 analysis protocols <sup>57</sup>. To conclude, a concentration of 5 ng/ml of target protein detection is  
14  
15 well in the range demonstrated by other LC-MS based assays. However, experiments spiking  
16  
17 lower concentrations of the target proteins are needed to determine the true limit of detection  
18  
19 of the AFFIRM assay. We are confident that further improvements can be implemented in the  
20  
21 workflow to reach closer to the pg/ml sensitivity range reported by other immunoassays, e.g.  
22  
23 well-developed ELISA assays <sup>19</sup>. Such improvements include the use of well-characterized  
24  
25 antibody pairs, having higher affinity, better specificity and preferable binding to different  
26  
27 epitopes. Also, we believe that the washing procedure can be optimized in order to remove  
28  
29 potential non-specific interactions that may lead to loss in sensitivity. We are also working to  
30  
31 remove the drying step after the trypsin digestion in the current protocol. Digesting directly in  
32  
33 folie-covered 96-well plates and subsequent direct LC-MS injection would most likely both  
34  
35 lower variability and increase sensitivity of the assay.  
36  
37  
38  
39

40  
41 In conclusion, we have developed a platform that allows for rapid development of novel  
42  
43 immunoaffinity LC-SRM assays through efficient selections of scFv antibodies for protein  
44  
45 capture and parallel development of LC-SRM assays for sequence based protein identification  
46  
47 and quantification. With this platform all requirements necessary for proteomics data to be  
48  
49 moved towards clinical assays are addressed; high sensitivity through specific antibody  
50  
51 enrichment, fully automated with high-throughput potential to minimize workload and  
52  
53 specificity through targeted SRM readout.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5 **Figure 1.** The AFFIRM platform. Target-specific single chain antibody fragments and SRM  
6 assays are developed in parallel to create collections or libraries (A). This allows for fast  
7 implementation of the AFFIRM assay through production of scFv in 96-well format and  
8 coupling to magnetic beads (B). The assay is run in a 96-well format with a 1-h incubation of  
9 coupled beads in serum samples followed by washes, on-bead digestion and direct LC-SRM  
10 analysis without any further sample cleanup (C).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 **Figure 2.** Specificity analysis of antibody fragments as determined by ELISA. Soluble  
22 recombinant antibody fragments C-Keratin19-1, C-Keratin19-3, MUC1-4, MUC1-5,  
23 BRCA1:10 and BRCA1:14 were investigated for their binding to recombinant protein (●)  
24 KRT19, MUC1-Fc and BRCA1, and negative control (■) BSA.  
25  
26  
27  
28  
29  
30  
31

32 **Figure 3.** Extracted ion chromatograms of the BRCA1 target peptide EKPELTASTER  
33 captured exemplifying signal readout in single- (A-D) and multiplexed (E-H) AFFIRM assay  
34 format. The blank captures (A and E) show a very low degree of background signal in both  
35 single and multiplexed formats.  
36  
37  
38  
39  
40  
41  
42  
43

44 **Figure 4.** Response curves for the enrichment of target protein in a serum background using  
45 phage-selected scFvs. Curves are obtained by plotting the SRM signal peak area against the  
46 spiked-in target protein concentration. The response curves were generated for a protein  
47 concentration range of 5-1000 ng/ml. Enrichment of KRT19 using two scFvs (A), BRCA1  
48 using two scFvs (B) and MUC1 using two scFvs (C) demonstrate that the target proteins can  
49 be detected down to the lowest concentration for all three proteins. The curves show very  
50 good linearity with a coefficient of determination ( $R^2$ ) of 0.99 for all three KRT19 peptides,  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 0.99 and 0.98 for the two MUC1 peptides while the two BRCA1 peptides provide slightly less  
4  
5 linearity with R2 values of 0.92 and 0.88 respectively.  
6  
7

8  
9 **Figure 5.** Multiplexed response curves in triplicate with standard deviations for the  
10 enrichment of target protein in a serum background using phage selected scFvs plotting area  
11 under chromatographic curve in the SRM signal against target protein concentration. The  
12 response curves were generated for a protein concentration range of 5-1000 ng/ml using all  
13 six scFv to enrich for the three target proteins in the same capture experiment. Two out of  
14 three target peptides for KRT19 were detected down to the lowest concentration (5 ng/ml) (A)  
15 and both peptides for MUC1 (B) and BRCA1 (C) respectively were detected down to the  
16 lowest concentration. Average CVs are summarized in Table 1.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

27  
28 **Table 1.** The three target proteins measured, their target peptides measured and corresponding  
29 median CV in multiplexed AFFIRM analysis.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## ASSOCIATED CONTENT

**Supporting Information**

The mass spectrometry data and transition list has been deposited to the PeptideAtlas SRM Experiment Library PASSEL ([www.peptideatlas.org/passell](http://www.peptideatlas.org/passell)). Transition lists are also provided as supplementary table S1.

## AUTHOR INFORMATION

**Corresponding Author**

Sofia Waldemarson, Department of Immunotechnology, Lund University, Medicon Village (House 406), SE-223 81 Lund, Sweden. Tel.: + 46 (0) 46 222 7469 (office). Email: Sofia.Waldemarson@immun.lth.se.

**Present Address**

<sup>1</sup> Department of Cell Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, GAC-1200; La Jolla, CA 92037, USA

<sup>2</sup>Department of Chemical and Systems Biology, Stanford School of Medicine, Stanford, CA, 94305, USA

**Author Contributions**

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

‡ These authors contributed equally

† These authors contributed equally

## Notes

The authors declare that there are no conflicts of interest.

## ACKNOWLEDGEMENTS

We would like to thank Peter James, Mats Mågård and Fredrik Levander for their help and support throughout the project and Filip Ottosson for help with scFv production and coupling. Also thanks to Anders Carlsson for contributing figure describing the phage display (Figure 1). This project was supported by grants from Swedish National Research Council (VR-M, SW), EU FP7 Grant Agreement 241481 (AFFINOMICS: Protein Binders for Characterisation of Human Proteome Function: Generation, Validation, Application) (AS and HP) and the Fru Berta Kamprads Stiftelse (SW).

## REFERENCES

- (1) Rifai, N.; Gillette, M. A.; Carr, S. A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. *Nat Biotechnol* **2006**, *24*, 971–983.
- (2) Anderson, N. L.; Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. *Mol Cell Proteomics* **2002**, *1*, 845–867.
- (3) Hüttenhain, R.; Malmström, J.; Picotti, P.; Aebersold, R. Perspectives of targeted mass spectrometry for protein biomarker verification. *Curr Opin Chem Biol* **2009**, *13*, 518–525.
- (4) Kartalov, E. P.; Lin, D. H.; Lee, D. T.; Anderson, W. F.; Taylor, C. R.; Scherer, A. Internally calibrated quantification of protein analytes in human serum by fluorescence immunoassays in disposable elastomeric microfluidic devices. *Electrophoresis* **2008**, *29*, 5010–5016.
- (5) Bock, J. L. The new era of automated immunoassay. *Am. J. Clin. Pathol.* **2000**, *113*, 628–646.
- (6) Prassas, I.; Brinc, D.; Farkona, S.; Leung, F.; Dimitromanolakis, A.; Chrystoja, C. C.; Brand, R.; Kulasingam, V.; Blasutig, I. M.; Diamandis, E. P. False Biomarker Discovery due to Reactivity of a Commercial ELISA for CUZD1 with Cancer Antigen CA125. *Clin Chem* **2013**.
- (7) Ellington, A. A.; Kullo, I. J.; Bailey, K. R.; Klee, G. G. Antibody-based protein multiplex platforms: technical and operational challenges. *Clin Chem* **2010**, *56*, 186–193.
- (8) Wang, Q.; Chaerkady, R.; Wu, J.; Hwang, H. J.; Papadopoulos, N.; Kopelovich, L.; Maitra, A.; Matthaei, H.; Eshleman, J. R.; Hruban, R. H.; et al. Mutant proteins as

- 1  
2  
3 cancer-specific biomarkers. *Proc Natl Acad Sci USA* **2011**, *108*, 2444–2449.
- 4 (9) Niederkofler, E. E.; Tubbs, K. A.; Gruber, K.; Nedelkov, D.; Kiernan, U. A.;  
5 Williams, P.; Nelson, R. W. Determination of beta-2 microglobulin levels in plasma  
6 using a high-throughput mass spectrometric immunoassay system. *Anal Chem* **2001**,  
7 *73*, 3294–3299.
- 8 (10) Trenchevska, O.; Kamcheva, E.; Nedelkov, D. Mass spectrometric immunoassay for  
9 quantitative determination of protein biomarker isoforms. *J Proteome Res* **2010**, *9*,  
10 5969–5973.
- 11 (11) Picotti, P.; Bodenmiller, B.; Mueller, L. N.; Domon, B.; Aebersold, R. Full dynamic  
12 range proteome analysis of *S. cerevisiae* by targeted proteomics. *Cell* **2009**, *138*, 795–  
13 806.
- 14 (12) Addona, T. A.; Abbatiello, S. E.; Schilling, B.; Skates, S. J.; Mani, D. R.; Bunk, D.  
15 M.; Spiegelman, C. H.; Zimmerman, L. J.; Ham, A.-J. L.; Keshishian, H.; et al.  
16 Multi-site assessment of the precision and reproducibility of multiple reaction  
17 monitoring-based measurements of proteins in plasma. *Nat Biotechnol* **2009**, *27*,  
18 633–641.
- 19 (13) Kitteringham, N. R.; Jenkins, R. E.; Lane, C. S.; Elliott, V. L.; Park, B. K. Multiple  
20 reaction monitoring for quantitative biomarker analysis in proteomics and  
21 metabolomics. *J Chromatogr B Analyt Technol Biomed Life Sci* **2009**, *877*, 1229–  
22 1239.
- 23 (14) Prakash, A.; Rezai, T.; Krastins, B.; Sarracino, D.; Athanas, M.; Russo, P.; Ross, M.  
24 M.; Zhang, H.; Tian, Y.; Kulasingam, V.; et al. Platform for establishing  
25 interlaboratory reproducibility of selected reaction monitoring-based mass  
26 spectrometry peptide assays. *J Proteome Res* **2010**, *9*, 6678–6688.
- 27 (15) Hoofnagle, A. N.; Becker, J. O.; Oda, M. N.; Cavigiolio, G.; Mayer, P.; Vaisar, T.  
28 Multiple-reaction monitoring-mass spectrometric assays can accurately measure the  
29 relative protein abundance in complex mixtures. *Clin Chem* **2012**, *58*, 777–781.
- 30 (16) Prakash, A.; Rezai, T.; Krastins, B.; Sarracino, D.; Athanas, M.; Russo, P.; Zhang,  
31 H.; Tian, Y.; Li, Y.; Kulasingam, V.; et al. Interlaboratory reproducibility of selective  
32 reaction monitoring assays using multiple upfront analyte enrichment strategies. *J*  
33 *Proteome Res* **2012**, *11*, 3986–3995.
- 34 (17) Shi, T.; Sun, X.; Gao, Y.; Fillmore, T. L.; Schepmoes, A. A.; Zhao, R.; He, J.; Moore,  
35 R. J.; Kagan, J.; Rodland, K. D.; et al. Targeted quantification of low ng/mL level  
36 proteins in human serum without immunoaffinity depletion. *J Proteome Res* **2013**,  
37 *12*, 3353–3361.
- 38 (18) Hüttenhain, R.; Soste, M.; Selevsek, N.; Röst, H.; Sethi, A.; Carapito, C.; Farrah, T.;  
39 Deutsch, E. W.; Kusebauch, U.; Moritz, R. L.; et al. Reproducible quantification of  
40 cancer-associated proteins in body fluids using targeted proteomics. *Sci Transl Med*  
41 **2012**, *4*, 142ra94.
- 42 (19) Weiß, F.; van den Berg, B. H. J.; Planatscher, H.; Pynn, C. J.; Joos, T. O.; Poetz, O.  
43 Catch and measure-mass spectrometry-based immunoassays in biomarker research.  
44 *Biochim. Biophys. Acta* **2013**.
- 45 (20) Anderson, N. L.; Anderson, N. G.; Haines, L. R.; Hardie, D. B.; Olafson, R. W.;  
46 Pearson, T. W. Mass spectrometric quantitation of peptides and proteins using Stable  
47 Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). *J Proteome*  
48 *Res* **2004**, *3*, 235–244.
- 49 (21) Whiteaker, J. R.; Zhao, L.; Abbatiello, S. E.; Burgess, M.; Kuhn, E.; Lin, C.; Pope,  
50 M. E.; Razavi, M.; Anderson, N. L.; Pearson, T. W.; et al. Evaluation of large scale  
51 quantitative proteomic assay development using peptide affinity-based mass  
52 spectrometry. *Mol Cell Proteomics* **2011**, *10*, M110.005645.
- 53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 (22) Jiang, J.; Parker, C. E.; Hoadley, K. A.; Perou, C. M.; Boysen, G.; Borchers, C. H.  
4 Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR  
5 diagnosis. *Proteomics Clin Appl* **2007**, *1*, 1651–1659.
- 6 (23) Krastins, B.; Prakash, A.; Sarracino, D. A.; Nedelkov, D.; Niederkofler, E. E.;  
7 Kiernan, U. A.; Nelson, R.; Vogelsang, M. S.; Vadali, G.; Garces, A.; et al. Rapid  
8 development of sensitive, high-throughput, quantitative and highly selective mass  
9 spectrometric targeted immunoassays for clinically important proteins in human  
10 plasma and serum. *Clin. Biochem.* **2013**, *46*, 399–410.
- 11 (24) McCafferty, J.; Griffiths, A. D.; Winter, G.; Chiswell, D. J. Phage antibodies:  
12 filamentous phage displaying antibody variable domains. *Nature* **1990**, *348*, 552–554.
- 13 (25) Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned  
14 antigens on the virion surface. *Science* **1985**, *228*, 1315–1317.
- 15 (26) Hallborn, J.; Carlsson, R. Automated screening procedure for high-throughput  
16 generation of antibody fragments. *BioTechniques* **2002**, *Suppl*, 30–37.
- 17 (27) Hust, M.; Meyer, T.; Voedisch, B.; Rülker, T.; Thie, H.; El-Ghezal, A.; Kirsch, M. I.;  
18 Schütte, M.; Helmsing, S.; Meier, D.; et al. A human scFv antibody generation  
19 pipeline for proteome research. *J. Biotechnol.* **2011**, *152*, 159–170.
- 20 (28) Turunen, L.; Takkinen, K.; Söderlund, H.; Pulli, T. Automated panning and screening  
21 procedure on microplates for antibody generation from phage display libraries. *J*  
22 *Biomol Screen* **2009**, *14*, 282–293.
- 23 (29) Schofield, D. J.; Pope, A. R.; Clementel, V.; Buckell, J.; Chapple, S. D.; Clarke, K.  
24 F.; Conquer, J. S.; Crofts, A. M.; Crowther, S. R. E.; Dyson, M. R.; et al. Application  
25 of phage display to high throughput antibody generation and characterization.  
26 *Genome Biol* **2007**, *8*, R254.
- 27 (30) Bäckström, M.; Link, T.; Olson, F. J.; Karlsson, H.; Graham, R.; Picco, G.; Burchell,  
28 J.; Taylor-Papadimitriou, J.; Noll, T.; Hansson, G. C. Recombinant MUC1 mucin  
29 with a breast cancer-like O-glycosylation produced in large amounts in Chinese-  
30 hamster ovary cells. *The Biochemical journal* **2003**, *376*, 677–686.
- 31 (31) Persson, H.; Lantto, J.; Ohlin, M. A focused antibody library for improved hapten  
32 recognition. *J. Mol. Biol.* **2006**, *357*, 607–620.
- 33 (32) Maclean, B.; Tomazela, D. M.; Shulman, N.; Chambers, M.; Finney, G. L.; Frewen,  
34 B.; Kern, R.; Tabb, D. L.; Liebler, D. C.; Maccoss, M. J. Skyline: an open source  
35 document editor for creating and analyzing targeted proteomics experiments.  
36 *Bioinformatics* **2010**, *26*, 966–968.
- 37 (33) Tang, N.; Tornatore, P.; Weinberger, S. R. Current developments in SELDI affinity  
38 technology. *Mass Spectrom Rev* **2004**, *23*, 34–44.
- 39 (34) Boja, E. S.; Jortani, S. A.; Ritchie, J.; Hoofnagle, A. N.; Tezak, Z.; Mansfield, E.;  
40 Keller, P.; Rivers, R. C.; Rahbar, A.; Anderson, N. L.; et al. The journey to regulation  
41 of protein-based multiplex quantitative assays. *Clin Chem* **2011**, *57*, 560–567.
- 42 (35) Olsson, N.; Wingren, C.; Mattsson, M.; James, P.; O'Connell, D.; Nilsson, F.; Cahill,  
43 D. J.; Borrebaeck, C. A. K. Proteomic analysis and discovery using affinity  
44 proteomics and mass spectrometry. *Mol Cell Proteomics* **2011**, *10*, M110.003962.
- 45 (36) Olsson, N.; Carlsson, P.; James, P.; Hansson, K.; Waldemarson, S.; Malmström, P.;  
46 Fernö, M.; Rydén, L.; Wingren, C.; Borrebaeck, C. A. K. Grading breast cancer  
47 tissues using molecular portraits. *Mol Cell Proteomics* **2013**.
- 48 (37) Waldemarson, S.; Krogh, M.; Alaiya, A.; Kirik, U.; Schedvins, K.; Auer, G.;  
49 Hansson, K.; Ossola, R.; Aebersold, R.; Lee, H.; et al. Protein expression changes in  
50 ovarian cancer during the transition from benign to malignant. *J Proteome Res* **2012**.
- 51 (38) Nordenfelt, P.; Waldemarson, S.; Linder, A.; Mörgelin, M.; Karlsson, C.;  
52 Malmström, J.; Björck, L. Antibody orientation at bacterial surfaces is related to  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- invasive infection. *J. Exp. Med.* **2012**, *209*, 2367–2381.
- (39) Végvári, A.; Sjödin, K.; Rezeli, M.; Marko-Varga, G. Quantification of human kallikrein-2 in clinical samples by selected reaction monitoring. *J Proteome Res* **2013**, *12*, 4612–4616.
- (40) Kuhn, E.; Addona, T.; Keshishian, H.; Burgess, M.; Mani, D. R.; Lee, R. T.; Sabatine, M. S.; Gerszten, R. E.; Carr, S. A. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. *Clin Chem* **2009**, *55*, 1108–1117.
- (41) Gerber, S. A.; Rush, J.; Stemman, O.; Kirschner, M. W.; Gygi, S. P. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. *Proc Natl Acad Sci USA* **2003**, *100*, 6940–6945.
- (42) Hoogenboom, H. R. Selecting and screening recombinant antibody libraries. *Nat Biotechnol* **2005**, *23*, 1105–1116.
- (43) Anderson, N. L.; Anderson, N. G.; Pearson, T. W.; Borchers, C. H.; Paulovich, A. G.; Patterson, S. D.; Gillette, M.; Aebersold, R.; Carr, S. A. A human proteome detection and quantitation project. *Mol Cell Proteomics* **2009**, *8*, 883–886.
- (44) Schoenherr, R. M.; Zhao, L.; Whiteaker, J. R.; Feng, L.-C.; Li, L.; Liu, L.; Liu, X.; Paulovich, A. G. Automated screening of monoclonal antibodies for SISCAPA assays using a magnetic bead processor and liquid chromatography-selected reaction monitoring-mass spectrometry. *J Immunol Methods* **2010**, *353*, 49–61.
- (45) Whiteaker, J. R.; Zhao, L.; Anderson, L.; Paulovich, A. G. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. *Mol Cell Proteomics* **2010**, *9*, 184–196.
- (46) Uhlen, M.; Hober, S. Generation and validation of affinity reagents on a proteome-wide level. *Journal of molecular recognition : JMR* **2009**, *22*, 57–64.
- (47) Bordeaux, J.; Welsh, A.; Agarwal, S.; Killiam, E.; Baquero, M.; Hanna, J.; Anagnostou, V.; Rimm, D. Antibody validation. *BioTechniques* **2010**, *48*, 197–209.
- (48) [affinomics.org](http://affinomics.org).
- (49) [commonfund.nih.gov](http://commonfund.nih.gov).
- (50) Anderson, N. L.; Razavi, M.; Pearson, T. W.; Kruppa, G.; Paape, R.; Suckau, D. Precision of heavy-light peptide ratios measured by maldi-tof mass spectrometry. *J Proteome Res* **2012**, *11*, 1868–1878.
- (51) Brun, V.; Masselon, C.; Garin, J.; Dupuis, A. Isotope dilution strategies for absolute quantitative proteomics. *J Proteomics* **2009**, *72*, 740–749.
- (52) Kuhn, E.; Whiteaker, J. R.; Mani, D. R.; Jackson, A. M.; Zhao, L.; Pope, M. E.; Smith, D.; Rivera, K. D.; Anderson, N. L.; Skates, S. J.; et al. Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. *Mol Cell Proteomics* **2012**, *11*, M111.013854.
- (53) Percy, A. J.; Chambers, A. G.; Yang, J.; Borchers, C. H. Multiplexed MRM-based quantitation of candidate cancer biomarker proteins in undepleted and non-enriched human plasma. *Proteomics* **2013**, *13*, 2202–2215.
- (54) Keshishian, H.; Addona, T.; Burgess, M.; Kuhn, E.; Carr, S. A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. *Mol Cell Proteomics* **2007**, *6*, 2212–2229.
- (55) Fortin, T.; Salvador, A.; Charrier, J. P.; Lenz, C.; Bettsworth, F.; Lacoux, X.; Choquet-Kastylevsky, G.; Lemoine, J. Multiple reaction monitoring cubed for protein quantification at the low nanogram/milliliter level in nondepleted human serum. *Anal Chem* **2009**, *81*, 9343–9352.


- 1  
2  
3 (56) Kushnir, M. M.; Rockwood, A. L.; Roberts, W. L.; Abraham, D.; Hoofnagle, A. N.;  
4 Meikle, A. W. Measurement of thyroglobulin by liquid chromatography-tandem mass  
5 spectrometry in serum and plasma in the presence of antithyroglobulin  
6 autoantibodies. *Clin Chem* **2013**, *59*, 982–990.
- 7 (57) Razavi, M.; Johnson, L. D. S.; Lum, J. J.; Kruppa, G.; Anderson, N. L.; Pearson, T.  
8 W. Quantification of a proteotypic peptide from protein C inhibitor by liquid  
9 chromatography-free SISCAPA-MALDI mass spectrometry: application to  
10 identification of recurrence of prostate cancer. *Clin Chem* **2013**, *59*, 1514–1522.
- 11 (58) Persson H.; Ye W.; Wernimont A.; Adams JJ.; Koide A.; Koide S.; Lam R.; Sidhu  
12 SS. CHR-H3 diversity is not required for antigen recognition by synthetic antibodies.  
13 *J Mol Biol* **2013**, *425*(4), 803-811.
- 14 (59) Fellouse, F. A. & Sidhu, S. S. Making antibodies in bacteria. In *Making and Using*  
15 *Anti- bodies* CRC Press **2007**, pp. 157–180.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1

Protein Name	Protein ID / Uniprot Accession Number	Peptide Sequence Targeted	Median CV (%)
Keratin, type I cytoskeletal 19 (KRT19)	P08727	FGPGVAFR	13.6
		LTMQNLNDR	12.0
		ILGATIENSR	11.2
Breast cancer type 1 susceptibility protein (BRCA1)	P38398	EKPELTASTER	30.6
		YFLGIAGGK	18.2
Mucin-1-Fc* (MUC1-Fc)	P15941/P01863	DLPAPIER	7.0
		TELNYK	9.6


\* MUC1-Fc is analyzed in AFFIRM using scFv targeting MUC1 and an SRM readout of two peptides from the Mouse Ig gamma-2A chain C region

## Abstract Graphic












1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60






160x156mm (300 x 300 DPI)



159x151mm (300 x 300 DPI)




159x122mm (300 x 300 DPI)



84x193mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



84x180mm (300 x 300 DPI)